In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells
- PMID: 8348563
- PMCID: PMC11038618
- DOI: 10.1007/BF01518517
In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells
Abstract
In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability > 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.
Similar articles
-
An analysis of autologous T-cell anti-tumour responses in colon-carcinoma patients following active specific immunization (ASI).Int J Cancer. 1992 Jul 30;51(6):878-85. doi: 10.1002/ijc.2910510608. Int J Cancer. 1992. PMID: 1639535 Clinical Trial.
-
Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.Cancer Immunol Immunother. 1990;32(3):173-8. doi: 10.1007/BF01771453. Cancer Immunol Immunother. 1990. PMID: 2289211 Free PMC article. Clinical Trial.
-
In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.Eur J Cancer. 1991;27(6):703-10. doi: 10.1016/0277-5379(91)90170-i. Eur J Cancer. 1991. PMID: 1829908
-
Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines.Cancer Surv. 1992;13:129-54. Cancer Surv. 1992. PMID: 1423321 Review.
-
Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.Cancer Metastasis Rev. 1987;5(4):299-312. doi: 10.1007/BF00055375. Cancer Metastasis Rev. 1987. PMID: 3552279 Review.
Cited by
-
Transcriptome Analysis of Natural Killer Cells in Response to Newcastle Disease Virus Infected Hepatocellular Carcinoma Cells.Genes (Basel). 2023 Apr 10;14(4):888. doi: 10.3390/genes14040888. Genes (Basel). 2023. PMID: 37107646 Free PMC article.
-
Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.Exp Ther Med. 2018 May;15(5):4522-4530. doi: 10.3892/etm.2018.5935. Epub 2018 Mar 8. Exp Ther Med. 2018. PMID: 29731836 Free PMC article.
-
Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.Cancer Immunol Immunother. 1992;35(5):325-30. doi: 10.1007/BF01741145. Cancer Immunol Immunother. 1992. PMID: 1394336 Free PMC article. Clinical Trial.
-
A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.Mol Med. 1998 Dec;4(12):783-94. Mol Med. 1998. PMID: 9990864 Free PMC article. Clinical Trial.
References
-
- Bier H, Armonat G, Bier J, Schirrmacher V, Ganzer U. Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model. Otorhinolaryngology. 1989;51:197. - PubMed
-
- Bohle W, Schlag P, Liebrich W, Hohenberger P, Manasterski M, Müller P, Schirrmacher V. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine: first clinical results with tumor cell vaccines modified with live but avirulent newcastle disease virus. Cancer. 1990;66:1517. - PubMed
-
- Dvorak HF, Galli SJ, Dvorak AM. Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol. 1986;17:122. - PubMed
-
- Fleischer B. Non-specific propagation of human antigen-dependent T lymphocyte clones. J Immunol Methods. 1988;109:215. - PubMed
-
- Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res. 1989;49:1621. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials